Video

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.

Lacey J. Padrón, PhD, vice president, Informatics, Parker Cancer Institute for Immunotherapy, discusses biosignatures found in a phase 2 study (NCT03214250) in pancreatic cancer.

In this open-label, multicenter trial, oncologists examined the efficacy of gemcitabine and nab-paclitaxel plus sotigalimab (Apexigen; formerly APX 005M) and/or nivolumab (Opdivo) in patients with metastatic pancreatic adenocarcinoma.

The study revealed biomarkers of response, particularly to the sotigalimab/chemotherapy and nivolumab/chemotherapy combinations, Padrón explains. Moreover, in the patients’ blood and tumor at baseline, investigators found signals that correlated with longer survival, Padrón adds.

Those biosignature were distinct for the 2 combinations, and they related closely to the mechanisms of action of sotigalimab and nivolumab, respectively, Padrón concludes.

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center